Camden South Family Doctors > Welcome > Meningococcal B Vaccine – Bexsero

Meningococcal B Vaccine – Bexsero

Meningococcus is a bacteria that is like the shark attack of the infectious world. It strikes with very little warning, death can occur and there is risk of losing a limb or two. Penicillin can fix it, but detecting it early is impossible. There are a 13 serotypes designated letters such as A, B, and C. Type B causes 80% of disease in Australia is responsible for nearly all the deaths. Type C has had an effective vaccine since 2003. But type B has a large number of strains which has made vaccine development difficult until now. Bexsero is the name given to the new vaccine and it covers around 80% of Meningococcus B strains in Australia and other parts of the World. It is not yet on the standard schedule but is recommended and can be obtained privately.

How common is it?

Meningococcal disease involves not only meningitis, but also invasive diseases such as septicaemia (blood poisoning). At present there are around 200 cases of meningococcal disease each year in Australia and 10% will die. The highest incidence are those under 5 years (about 50 – 60 cases per year) and those under 12 months have a higher incidence of death. Once it hits the bloodstream the infection spreads and the calamitous cascade of chemicals and toxins released causes systems mayhem resulting in shock, septicaemia, meningitis and destruction of blood vessels. This can happen so fast – a few hours that early detection is virtually impossible. Interestingly this bacteria actually lives happily in the throat of about 10% of adults. It causes no problems and is impossible to eradicate. (Time will tell whether the vaccination lowers the carriage rate). However when the right conditions occur, and the bacteria has a portal of entry, such as when there is a cold and there is inflamed mucousal tissue it can strike quickly.

Meningococcal B vaccine – Bexsero

The vaccine works similar to the other vaccines for bacteria like this. Bits of meningococcal proteins are attached to carriers that introduce the proteins to immunological cells which analyse and then produce antibodies against these proteins. These antibodies are then added to the bank of memory antibodies to be activated when there is contact with this protein in the future.

meningococcal proteins – though inactive – are still potent and so this vaccine will cause side effects as the immune system fires up the antibodies. These typical side effects include fever, localised soreness at the sight of the injection and irritability for a day or two. This vaccine is therefore recommended to be given with panadol.

Who Should Get the Vaccine

# Anyone can get the vaccine but the current guidelines recommend the current high risk groups.

# Infants and young children, particularly under 24 months.

# Adolescents aged 15 to 19.

# Children and adults with conditions that place them at a high risk, such as problems with immunity or an absent spleen.

How much does it cost?

Currently it is $140 to $150 per vaccination. Some General Practices will carry this vaccination, otherwise you will need a script to get this from the pharmacy. But beware of ensuring you maintain the ‘cold chain’ prior to use.